NEW YORK (GenomeWeb) – Metabolon announced today that it has partnered with Israeli precision medicine firm InnVentis to study metabolomics in individuals with chronic inflammatory diseases such as rheumatoid arthritis.
The deal joins Metabolon's metabolomics expertise with InnVentis' big data and machine learning platform, the company said. Specific terms of the partnership were not disclosed.
"Our goal is to use our proprietary technology in conjunction with InnVentis' platform to provide a more accurate health assessment of patients, as well as clinically useful information," Metabolon CEO John Ryals said in a statement. "Metabolomics may help answer key biological questions about these complex disorders and improve personalized treatment."
InnVentis CEO Thomas Wilckens added that his company is aiming to use metabolomics and other omics technologies "to enable novel, real-time disease management for clinicians and patients.. This will include drug responder identification upon first diagnosis, as well as drug dosing management."